[1] Finn R S, Crown J P, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18):A randomised phase 2 study[J]. The Lancet Oncology, 2015, 16(1):25-35. [2] Macedo F, Ladeira K, Pinho F, et al. Bone metastases:An overview[J]. Oncology Reviews, 2017, 11(1):321. [3] Guo R R, Lu G L, Qin B J, et al. Ultrasound imaging technologies for breast cancer detection and management:A review[J]. Ultrasound in Medicine & Biology, 2018, 44(1):37-70. [4] DeSantis C E, Fedewa S A, Goding Sauer A, et al. Breast cancer statistics, 2015:Convergence of incidence rates between black and white women[J]. CA:A Cancer Journal for Clinicians, 2016, 66(1):31-42. [5] Nutter F, Holen I, Brown H K, et al. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone:Evidence using a novel bone-seeking cell line[J]. Endocrine-Related Cancer, 2014, 21(2):327-341. [6] Pang X C, Gong K, Zhang X D, et al. Osteopontin as a multifaceted driver of bone metastasis and drug resistance[J]. Pharmacological Research, 2019, 144:235-244. [7] 谷英士, 李颖嘉, 文戈, 等. 超声弹性成像与常规超声诊断乳腺癌腋淋巴结转移[J]. 中国医学影像技术, 2014, 30(11):1661-1664. [8] 林盈, 薛恩生, 林礼务, 等. 高频彩色多普勒超声诊断乳腺癌腋窝淋巴结转移的价值[J]. 中华医学超声杂志(电子版), 2009, 6(1):59-65. [9] Wei R, Wong J P C, Kwok H F. Osteopontin:A promising biomarker for cancer therapy[J]. Journal of Cancer, 2017, 8(12):2173-2183. [10] Zhao H L, Chen Q, Alam A, et al. The role of osteopontin in the progression of solid organ tumour[J]. Cell Death & Disease, 2018, 9(3):356. [11] Tulotta C, Ottewell P. The role of IL-1B in breast cancer bone metastasis[J]. Endocrine-related Cancer, 2018, 25(7):R421-R434. [12] Sosnoski D M, Norgard R J, Grove C D, et al. Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment[J]. Clinical & Experimental Metastasis, 2015, 32(4):335-344. [13] Escobar P, Bouclier C, Serret J, et al. IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production[J]. Oncotarget, 2015, 6(30):29034-29047. |